MoonLake Immunotherapeutics（纳斯达克代码：MLTX）宣布，其候选药物sonelokimab用于治疗掌跖脓疱病（PPP）已获得美国食品药品监督管理局（FDA）的快速通道资格认定。
此次认定将有助于加速该药物的开发和审评进程，为患有这一慢性、衰弱性皮肤病的患者带来新的治疗希望。掌跖脓疱病是一种罕见的炎症性皮肤病，目前治疗选择有限。
同时，公司公布了即将举行的投资者日的详细安排。此次活动将向投资者和分析师深入介绍公司的研发管线、战略规划以及sonelokimab的最新临床进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.